eligibility_summary
Adults 18–75 with WHO-defined HL or B‑cell/indolent NHL relapsed/refractory after ≥2 lines (incl post‑ASCT), CD70 ≥10%, measurable disease, ECOG ≤2, >3‑mo prognosis, adequate organ function, prior toxicity ≤G1, successful leukapheresis, contraception, consent. Exclude: steroids/immunosuppression, recent therapy/surgery/vaccine, active infections (HIV/HBV/HCV), CNS disease, other recent cancers, prior allograft/allo‑HSCT or CD70 therapy, pregnancy/lactation, severe comorbidity, other trial.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT05948033 (Phase I/II). Intervention: Autologous CD70-targeted CAR-T cells (gene-modified cellular immunotherapy). Mechanism: Patient T cells are engineered ex vivo to express a chimeric antigen receptor that binds CD70 (ligand of CD27, a TNF-receptor family member). Upon CD70 engagement, CAR signaling (CD3ζ ± costimulatory domains) activates T cells to proliferate and kill CD70+ lymphoma cells via cytotoxic pathways, aiming to eliminate tumors and disrupt pro-survival CD70–CD27 signaling. Lymphodepletion: fludarabine (purine analog antimetabolite) and cyclophosphamide (alkylating agent) given pre-infusion to enhance CAR-T expansion/persistence. Targets: CD70-expressing malignant cells in DLBCL, MCL, FL, Hodgkin lymphoma, and other R/R lymphomas, focuses on the CD70/CD27 axis on tumor cells. Dose: 1×10^6, 3×10^6, 1×10^7 cells/kg, expansion at RP2D.